Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
    • Transcripts
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Nora AI
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team

You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?

Faron Pharmaceuticals Capital Markets Day 2024

By Inderes
Faron Pharmaceuticals

The agenda is as follows:

  • Opening remarks
  • Faron's strategy and key focus areas - Dr. Juho Jalkanen, MD, PhD, CEO
  • BEXMAB clinical data - Dr. Mika Kontro, MD, PhD, principal investigator of the BEXMAB trial
  • BEXMAB MDS market assessment - Mr. Ralph Hughes, MSc, BSc
  • Faron's development plan for solid tumors - Dr. Petri Bono, MD, PhD, CMO
  • Who benefits from bexmarilimab and why - Future Addressable Markets - Dr. Maija Hollmén, PhD, CSO
  • Q&A session
  • Closing remarks

More information regarding Faron Pharmaceuticals CMD 2024

Stay up to date
CMD

Recent videos

Herantis Pharma Plc, Phase 1b biomarker data webcast
08.01.2026 klo 12.00 Herantis Pharma
Investor Day | Nov. 24, 2025
23.12.2025 klo 12.00 United Bankers
Talenom - Planned demerger and strategies of Talenom and Easor
18.12.2025 klo 12.00 Talenom
Investing in the life science sector
18.12.2025 klo 08.47
Life Science Companies as Investments | Life Science Night Dec. 9, 2025
16.12.2025 klo 09.30 Aiforia Technologies
View all videos
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.